BNP/CALL/MERCK & CO./130/0.1/17.01.25 | Delayed Deutsche Boerse AG 15:20:35 2024-06-12 EDT | ||
| 0.88 EUR | -7.37% |
|
| Current month | +41.79% | ||
| 3 months | +46.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MERCK & CO., INC.
Latest news about MERCK & CO., INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-12 | 0.88 | -7.37% |
| 24-06-11 | 0.95 | +2.15% |
| 24-06-10 | 0.93 | +5.68% |
| 24-06-07 | 0.88 | +1.15% |
| 24-06-06 | 0.87 | +2.35% |
Delayed Quote Deutsche Boerse AG
Last update June 12, 2024 at 03:20 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MERCK & CO., INC. |
| Issuer | 
BNP Paribas
|
| WKN | PE89AL |
| ISIN | DE000PE89AL5 |
| Date issued | 2023-02-16 |
| Strike | 130 $ |
| Maturity | 2025-01-17 (219 Days) |
| Parity | 10 : 1 |
| Emission price | 0.61 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.21 € |
|---|---|
| Lowest since issue | 0.14 € |
| Spread | 0.01 € |
| Spread % | 1.14% |
Company Profile
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
-
Consensus: Merck & Co., Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
131.8
USD
Average target price
142.7
USD
Spread / Average Target
+8.22%
- Stock Market
- Warrants
- Warrant
